Skip to main content
Premium Trial:

Request an Annual Quote

ABI Names New Molecular Biology Head; Third Wave Tweaks Top Brass; Lee Hood Lands on Lumera s SAB; Illumina Taps Holden for Corporate Development; CuraGen Names New CEO; Invitrogen CEO Becomes BIO Director; and Others

NEW YORK, April 19 (GenomeWeb News) - Applied Biosystems announced this week that Mark Stevenson has been appointed president of the firm's molecular biology division. He previously served as president of the firm's applied markets division. Stevenson succeeds William Murray, who has resigned due to personal reasons.


ABI also announced that Leonard Klevan has replaced Stevenson as president of the applied markets division. Klevan had joined ABI earlier this year as vice president of R&D for applied markets. Before joining ABI, he was CEO of ReliaGene Technologies. He also is a former president and CEO of MiraiBio, a subsidiary of Hitachi Software Engineering, and had managed technology acquisitions and business development at Life Technologies, which was acquired by Invitrogen in 2000.

Third Wave Technologies has made two new appointments to its senior management team: Jorge Garces has been appointed vice president of product and platform development, and Cindy Ahn has been appointed vice president and general counsel


Garces joined Third Wave from Genzyme Genetics in October 2005 as executive director of clinical development. He served as director of molecular research and development at Genzyme Genetics, where he oversaw the technology and product development activities of laboratory staff in New York, Los Angeles, and Westborough, Mass.He earned his BS in biology from BrooklynCollegeand his PhD in cell and molecular biology from the CityUniversity of New York.


Ahn joins Third Wave from the Kirkland & Ellis law firm, where she was a partner and "key" member of the team that successfully litigated Third Wave's patent infringement suit against Stratagene. As GenomeWeb News reported, that suit resulted in a $20.1-million award to Third Wave. Ahn has a BS in biology from the Universityof Illinoisand her law degree from AmericanUniversity's Washington College of Law.

Leroy Hood, president and co-founder of Institute for Systems Biology, and Josh LaBaer, founder and director of the Instituteof Proteomicsat Harvard Medical School, have joined Lumera's scientific advisory board.

Ciphergen Biosystems has appointed Kenneth Conway to its board. Conwayfounded Millennium Predictive Medicine and Vitivity, both of which focus on the predictive medicine arena. He holds a BS from RutgersUniversityand attended the Executive Program at Dartmouth College's Dartmouth Institute, Tuck School of Business Administration.

Illumina has appointed Arthur Holden as senior vice president of corporate and market development, a new position. Holden will be charged with "developing relationships and partnerships with key customers in the pharmaceutical industry, large-scale research consortia and governmental bodies including the NIH and the US Food and Drug Administration," Illumina said. He will also serve as Illumina's representative on the Personalized Medicine Coalition and also help lead content development strategies for the company's products, "particularly those being developed for molecular diagnostics and clinical applications."


Holden was most recently chairman, CEO, and principal founder of First Genetic Trust. He is chairman of the Pharmaceutical Biomedical Research Consortium and the DMD Translational Research Consortium. Holden was formerly CEO of the SNP Consortium and CEO and a director of Celsis International, an industrial biotechnology company. He has an MBA from the J.L. Kellogg Graduate School of Management and a BS from UnionCollege.

Sigma-Aldrich has named Carl Turza chief information officer, effective May 1. Turza, 47, has worked at W.W. Grainger, AlliedSignal Aerospace, and other "large and complex" organizations. He holds an MBA from the University of Illinois in Chicago and a BA in economics from the University of Illinois in Champaign.

Alnylam Pharmaceuticals President and Chief Executive Officer John Maraganore and Invitrogen CEO Greg Lucier have been appointed to the board of directors of the Biotechnology Industry Organization. They will serve three-year terms.

CuraGen has appointed Frank Armstrong president and chief executive officer, and has elected Robert Patricelli as non-executive chairman of the board.

Armstrong replaces CuraGen founder Jonathan Rothberg, who stepped down in May 2005. Rothberg currently serves as a member on the CuraGen board and is chairman of CuraGen subsidiary 454 Life Sciences.


Armstrong was appointed to the CuraGen board in 2005, and will continue to serve as a member and will become a member of the 454 board. He holds degrees in biochemistry and medicine from the Universityof Edinburgh in Scotland.


Patricelli is CEO of Evolution Benefits and of Women's Health USA, and has been a CuraGen director since 1997.

BD Biosciences announced that it has promoted William Rhodes to the position of president, cell analysis. The unit has been restructured and Rhodeshas taken on additional responsibilities including the sales and technical service organizations.  Previously, Rhodeswas vice president/general manager for Cell Analysis.


He holds an MS in international business from Seton Hall University and a BS from CornellUniversity.

Upstream Biosciences has appointed Tim Fernback as chief financial officer. Since 2002, Fernback has been an active director of the Okanagan Capital Fund, an Okanagan, Canada--based technology venture fund. He is a graduate of McMasterUniversity, where he studied molecular biology and biochemistry, and also a graduate of the Universityof British Columbia, where he completed his MBA with a concentration in finance.

ArQule has made several changes in its management and board of directors "that reflect its transition to a sustainable research and development-based company from a chemical services business," the company said.


Specifically, the company appointed Peter Lawrence to the new position of general counsel and chief business officer. Also, Chief Financial Officer Louise Mawhinney will "depart" but will remain with ArQule until the completion of a search for her successor. ArQule has also initiated a "retained search" for a chief medical officer.


Lawrenceis currently a general partner of Pod Holding, a $100-million international venture capital firm in Bostonof which he was a founding partner in 2001. He holds a BA from AmherstCollegeand a JD from BostonUniversity School of Law.


ArQule has also named as a director Nancy Simonian, who is currently senior vice president of clinical, medical and regulatory affairs at Millennium Pharmaceuticals. Additionally, Laura Avakian, a director, will resign on May 12, and Werner Cautreels, another director, resigned last week. Cautreels will remain with ArQule as a member of the company's scientific advisory board.

EXACT Sciences said Harry Wilcox, currently senior vice president and chief financial officer and treasurer, will step down and assume the part-time role of senior vice president of corporate development. Jeffrey Luber, currently general counsel and secretary of EXACT Sciences, will replace him as treasurer and CFO.


Additionally, Chuck Carelli, controller of EXACT Sciences since November 2004, has been promoted to vice president of finance.


Luber has been with the company since November 2002. He has a JD and an MBA from SuffolkUniversity.


Carelli has served as controller and principal accounting officer at EXACT Sciences since November 2004. He is a certified public accountant and holds a BA in accounting from AssumptionCollege.

Exagen Diagnostics has hired Katharine Hawes as director of manufacturing, and Catherine Michael as director of customer care. Hawes will be based in Exagen's Albuquerque, NM, office and Michael will be based in Austin, Texas. Both are new positions.


Hawes comes to Exagen from Bioarray Solutions in Warren NJ, where she was retained as a consultant to establish current good manufacturing Practice and associated infrastructure.


Michael, before joining Exagen, was head of client services at Austin-based Esoterix, where she established two centralized client services call centers.

Harry Glorikian, partner and management consultant of TSG Partner's Bostonoffice, has been asked by the Charles Stark Draper Laboratory to become a member of its biomedical advisory board.


Glorikian currently leads the New Englandoffice of TSG Partners, including the management of consulting teams, new business development, and intellectual capital development.

Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.